Suppr超能文献

指导川崎病初始静脉注射免疫球蛋白治疗后再治疗的参数。

Parameters to guide retreatment after initial intravenous immunoglobulin therapy in kawasaki disease.

机构信息

Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Korea.

出版信息

Korean Circ J. 2011 Jul;41(7):379-84. doi: 10.4070/kcj.2011.41.7.379. Epub 2011 Jul 30.

Abstract

BACKGROUND AND OBJECTIVES

We sought to determine parameters to guide the decision of retreatment in patients with Kawasaki disease (KD) who remained febrile after initial intravenous immunoglobulin (IVIG).

SUBJECTS AND METHODS

A total of 129 children with KD were studied prospectively. Patients were treated with IVIG 2 to 9 days after the onset of disease. Laboratory measures, such as white blood cell (WBC), percentage of neutrophils, C-reactive protein (CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP), were determined before and 48 to 72 hours after IVIG treatment. Patients were classified into IVIG-responsive and IVIG-resistant groups, based on the response to IVIG.

RESULTS

Of a total of 129 patients, 107 patients (83%) completely responded to a single IVIG therapy and only 22 patients (17%) required retreatment: 14 had persistent fever and 8 had recrudescent fever. There was no significant difference between the groups in age, gender distribution, and duration of fever to IVIG initiation, but coronary artery lesions developed significantly more often in the resistant group than in the responsive group (31.8% vs. 2.8%, p=0.000). Compared with pre-IVIG data, post-IVIG levels of WBC, percentage of neutrophils, CRP, and NT-proBNP decreased to within the normal range in the responsive group, whereas they remained high in the resistant group. Multivariate logistic regression indicated that neutrophil counts, CRP, and NT-proBNP were independent parameters of retreatment.

CONCLUSION

Additional therapy at an early stage of the disease should be administered for febrile patients who have high values of CRP, NT-proBNP, and/or neutrophil counts after IVIG therapy.

摘要

背景与目的

我们旨在确定川崎病(KD)患者在初始静脉注射免疫球蛋白(IVIG)后仍发热时进行再治疗的指导参数。

对象与方法

前瞻性研究了 129 例 KD 患儿。患者在发病后 2-9 天接受 IVIG 治疗。在 IVIG 治疗前和治疗后 48-72 小时,测定白细胞(WBC)、中性粒细胞百分比、C 反应蛋白(CRP)和 N 端脑钠肽前体(NT-proBNP)等实验室指标。根据 IVIG 治疗的反应,将患者分为 IVIG 反应组和 IVIG 抵抗组。

结果

在总共 129 例患者中,107 例(83%)患者对单次 IVIG 治疗完全反应,仅 22 例(17%)需要再治疗:14 例持续发热,8 例复发发热。两组在年龄、性别分布和发热至 IVIG 开始的时间上无显著差异,但抵抗组冠状动脉病变的发生率明显高于反应组(31.8%比 2.8%,p=0.000)。与 IVIG 前数据相比,反应组 IVIG 后 WBC、中性粒细胞百分比、CRP 和 NT-proBNP 水平降至正常范围内,而抵抗组仍较高。多变量逻辑回归表明,中性粒细胞计数、CRP 和 NT-proBNP 是再治疗的独立参数。

结论

对于 IVIG 治疗后 CRP、NT-proBNP 和/或中性粒细胞计数较高的发热患者,应在疾病早期给予额外治疗。

相似文献

1
Parameters to guide retreatment after initial intravenous immunoglobulin therapy in kawasaki disease.
Korean Circ J. 2011 Jul;41(7):379-84. doi: 10.4070/kcj.2011.41.7.379. Epub 2011 Jul 30.
2
Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease.
Korean Circ J. 2014 Nov;44(6):415-22. doi: 10.4070/kcj.2014.44.6.415. Epub 2014 Nov 25.
4
Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.
BMC Pediatr. 2021 Sep 16;21(1):406. doi: 10.1186/s12887-021-02876-w.
5
A Comprehensive Assessment of the Value of Laboratory Indices in Diagnosing Kawasaki Disease.
Arthritis Rheumatol. 2015 Jul;67(7):1943-50. doi: 10.1002/art.39112.
6
Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Pediatr Rheumatol Online J. 2017 Mar 21;15(1):17. doi: 10.1186/s12969-017-0149-1.
7
Predictive factors of resistance to intravenous immunoglobulin and coronary artery lesions in Kawasaki disease.
Korean J Pediatr. 2016 Dec;59(12):477-482. doi: 10.3345/kjp.2016.59.12.477. Epub 2016 Dec 31.

引用本文的文献

5
Risk Factors of Coronary Artery Abnormality in Children With Kawasaki Disease: A Systematic Review and Meta-Analysis.
Front Pediatr. 2019 Sep 26;7:374. doi: 10.3389/fped.2019.00374. eCollection 2019.
7
Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease.
Korean J Pediatr. 2019 Apr;62(4):119-123. doi: 10.3345/kjp.2019.00150. Epub 2019 Mar 15.
9
Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children.
Korean J Pediatr. 2017 Apr;60(4):112-117. doi: 10.3345/kjp.2017.60.4.112. Epub 2017 Apr 25.

本文引用的文献

1
Infliximab treatment for refractory kawasaki disease in korean children.
Korean Circ J. 2010 Jul;40(7):334-8. doi: 10.4070/kcj.2010.40.7.334. Epub 2010 Jul 26.
2
Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease.
Pediatr Cardiol. 2009 Aug;30(6):810-7. doi: 10.1007/s00246-009-9441-2. Epub 2009 Apr 14.
3
Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.
Circulation. 2006 Jun 6;113(22):2606-12. doi: 10.1161/CIRCULATIONAHA.105.592865. Epub 2006 May 30.
4
Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease.
Pediatr Int. 2005 Jun;47(3):305-10. doi: 10.1111/j.1442-200x.2005.02049.x.
5
Infliximab treatment for refractory Kawasaki syndrome.
J Pediatr. 2005 May;146(5):662-7. doi: 10.1016/j.jpeds.2004.12.022.
7
Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
J Pediatr. 2004 Apr;144(4):496-9. doi: 10.1016/j.jpeds.2003.12.033.
8
Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease.
Eur J Pediatr. 2002 Oct;161(10):538-41. doi: 10.1007/s00431-002-1018-5. Epub 2002 Aug 16.
9
Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
J Pediatr. 2002 Apr;140(4):450-5. doi: 10.1067/mpd.2002.122469.
10
Serum levels of neutrophil activation cytokines in Kawasaki disease.
Pediatr Int. 2001 Apr;43(2):115-9. doi: 10.1046/j.1442-200x.2001.01362.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验